Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01321554
First received: March 10, 2011
Last updated: December 18, 2014
Last verified: November 2014